KR20220106960A - 경구 제약 즉시 방출 조성물 및 체중 감량을 위한 치료 방법 - Google Patents

경구 제약 즉시 방출 조성물 및 체중 감량을 위한 치료 방법 Download PDF

Info

Publication number
KR20220106960A
KR20220106960A KR1020227013390A KR20227013390A KR20220106960A KR 20220106960 A KR20220106960 A KR 20220106960A KR 1020227013390 A KR1020227013390 A KR 1020227013390A KR 20227013390 A KR20227013390 A KR 20227013390A KR 20220106960 A KR20220106960 A KR 20220106960A
Authority
KR
South Korea
Prior art keywords
denatonium
oral
formulation
pharmaceutical
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227013390A
Other languages
English (en)
Korean (ko)
Inventor
젠후안 젱
티엔-리 리
Original Assignee
알드바크 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알드바크 테라퓨틱스 인크. filed Critical 알드바크 테라퓨틱스 인크.
Publication of KR20220106960A publication Critical patent/KR20220106960A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020227013390A 2019-09-25 2020-09-24 경구 제약 즉시 방출 조성물 및 체중 감량을 위한 치료 방법 Pending KR20220106960A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905943P 2019-09-25 2019-09-25
US62/905,943 2019-09-25
PCT/US2020/052588 WO2021062061A1 (en) 2019-09-25 2020-09-24 Oral pharmaceutical immediate release composition and method of treatment for weight loss

Publications (1)

Publication Number Publication Date
KR20220106960A true KR20220106960A (ko) 2022-08-01

Family

ID=75167128

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227013390A Pending KR20220106960A (ko) 2019-09-25 2020-09-24 경구 제약 즉시 방출 조성물 및 체중 감량을 위한 치료 방법

Country Status (8)

Country Link
US (1) US20220280457A1 (https=)
EP (1) EP4034082A4 (https=)
JP (1) JP7680762B2 (https=)
KR (1) KR20220106960A (https=)
CN (2) CN114786647B (https=)
AU (1) AU2020354634A1 (https=)
CA (1) CA3151431A1 (https=)
WO (1) WO2021062061A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215858A1 (en) * 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound
WO2023064480A1 (en) 2021-10-14 2023-04-20 Aardvark Therapeutics Inc. Monohydrate salt of denatonium acetate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
KR20040063616A (ko) * 2003-01-08 2004-07-14 김원호 다이어트 식품용 조제
EP1991054A4 (en) * 2005-11-10 2012-04-25 Univ Minnesota SYSTEMIC PLANT STRENGTHENER
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
EP2582367A4 (en) * 2010-06-17 2013-11-27 California Inst Of Techn METHOD AND SYSTEM FOR MODULATING HORMONES AND RELATED METHODS, ACTIVE SUBSTANCES AND COMPOSITIONS
EP2661266B1 (en) * 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
EP3138900A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Detergent compositions and wrapping films therefor having at least two different aversive agents and methods related thereto
EP3138897A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Films at least 80 microns thick comprising aversive agents, unit dose detergent articles wrapped therein, uses and methods related thereto
EP3138898A1 (en) * 2015-09-04 2017-03-08 The Procter and Gamble Company Water-soluble detergent articles wrapped in a film with an aversive agent mainly in the flanges or skirt thereof
US10835505B2 (en) 2018-06-11 2020-11-17 Aardvark Therapeutics, Inc. Oral pharmaceutical formulation for weight loss, diabetes and related disorders
US12201593B2 (en) 2018-07-02 2025-01-21 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for asthma
WO2020014494A1 (en) * 2018-07-11 2020-01-16 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
EP4081201A4 (en) * 2019-12-24 2024-01-10 Aardvark Therapeutics Inc. Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders

Also Published As

Publication number Publication date
AU2020354634A1 (en) 2022-04-14
CA3151431A1 (en) 2021-04-01
EP4034082A4 (en) 2023-07-05
WO2021062061A1 (en) 2021-04-01
JP2022549833A (ja) 2022-11-29
CN114786647B (zh) 2025-05-06
CN120420287A (zh) 2025-08-05
US20220280457A1 (en) 2022-09-08
EP4034082A1 (en) 2022-08-03
CN114786647A (zh) 2022-07-22
JP7680762B2 (ja) 2025-05-21

Similar Documents

Publication Publication Date Title
US10835505B2 (en) Oral pharmaceutical formulation for weight loss, diabetes and related disorders
US8513439B2 (en) Antidepressant oral pharmaceutical compositions
US8455667B2 (en) Duloxetine compositions in the form of a powder for suspension in a liquid
US20120202820A1 (en) Pharmaceutical composition having the active substances metformin and sitagliptin or vildagliptin
EP3746058B1 (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
CN101663026A (zh) 氨基甲酸苯基烷基酯组合物
KR101136655B1 (ko) 레보타이록신 나트륨을 포함하는 제약 제제
US20220280457A1 (en) Oral pharmaceutical immediate release composition and method of treatment for weight loss
JPWO2004066998A1 (ja) 安定な経口用固形医薬組成物
US20060018962A1 (en) Sustained release formulation of tramadol
KR20160012706A (ko) 서방성 제제
US20220087960A1 (en) Oral Pharmaceutical Immediate Release Composition
CN100404025C (zh) 含有盐酸曲马多和对乙酰氨基酚的口崩片及其制备方法
CN111867578A (zh) 包含帕马考昔及普瑞巴林的用于治疗疼痛的药剂学组合物
CN116999403A (zh) 地昔帕明类似物及其口服胶囊制剂
US20050089558A1 (en) Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
RU2818092C1 (ru) Фармацевтическая композиция, включающая мелатонин и дифенгидрамин или его фармацевтически приемлемую соль, лекарственная форма на основе фармацевтической композиции, включающей мелатонин и дифенгидрамин или его фармацевтически приемлемую соль, способ получения и применение лекарственной формы на основе фармацевтической композиции, включающей мелатонин и дифенгидрамин или его фармацевтически приемлемую соль
JP4695326B2 (ja) 鼻炎用医薬組成物
JP2009235093A (ja) 鼻炎用医薬組成物
JPH02142732A (ja) 肥満並びに肥満に関連する各種疾患の治療剤
WO2026087536A1 (en) Methods of using homotaurine and analogs thereof for the treatment of glucagon-like peptide 1 receptor agonist induced gastrointestinal side effects
KR100701409B1 (ko) 호박산 수마트립탄을 함유하는 약제학적 조성물
RU2264814C2 (ru) Антигистаминная фармацевтическая композиция
WO2023106959A1 (ru) Фармацевтическая композиция, включающая мелатонин и дифенгидрамин или его фармацевтически приемлемую соль
WO2022084811A1 (en) Combination of plants and their use in the treatment of chronic persistent or neuropathic pain

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000